Progyny, Inc. Revenue from Contract with Customer, Including Assessed Tax
Progyny, Inc. (PGNY) reported Revenue from Contract with Customer, Including Assessed Tax of $286.63 million for the 3-month period ending 2024-09-30, per its 10-Q filed 2024-11-12.
Financial Statements › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax · last filed 2024-11-12
- Progyny, Inc. revenue from contract with customer, including assessed tax for the quarter ending 2024-09-30 was $286.63M, a 2.04% increase year-over-year.
- Progyny, Inc. revenue from contract with customer, including assessed tax for the quarter ending 2024-06-30 was $304.09M, a 8.85% increase year-over-year.
- Progyny, Inc. revenue from contract with customer, including assessed tax for the quarter ending 2024-03-31 was $278.08M, a 7.62% increase year-over-year.
- Progyny, Inc. revenue from contract with customer, including assessed tax for the quarter ending 2023-09-30 was $280.89M, a 36.77% increase year-over-year.
- Progyny, Inc. revenue from contract with customer, including assessed tax for fiscal 2021 was $500.62M, a 45.17% increase from fiscal 2020.
- Progyny, Inc. revenue from contract with customer, including assessed tax for fiscal 2020 was $344.86M, a 50.15% increase from fiscal 2019.
- Progyny, Inc. revenue from contract with customer, including assessed tax for fiscal 2019 was $229.68M, a 117.92% increase from fiscal 2018.
- Progyny, Inc. revenue from contract with customer, including assessed tax for fiscal 2018 was $105.40M, a 116.94% increase from fiscal 2017.
| Period end | Revenue from Contract with Customer, Including Assessed Tax 3 month | Revenue from Contract with Customer, Including Assessed Tax 6 month | Revenue from Contract with Customer, Including Assessed Tax 9 month | Revenue from Contract with Customer, Including Assessed Tax 12 month |
|---|---|---|---|---|
| 2024-09-30 | $286.63M 10-Q · filed 2024-11-12 | $590.71M derived: sum of 2 quarters · filed 2024-11-12 | $868.79M 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $304.09M 10-Q · filed 2024-08-07 | $582.16M 10-Q · filed 2024-08-07 | ||
| 2024-03-31 | $278.08M 10-Q · filed 2024-05-10 | |||
| 2023-09-30 | $280.89M 10-Q · filed 2024-11-12 | $560.26M derived: sum of 2 quarters · filed 2024-11-12 | $818.66M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $279.37M 10-Q · filed 2024-08-07 | $537.77M 10-Q · filed 2024-08-07 | ||
| 2023-03-31 | $258.39M 10-Q · filed 2024-05-10 | |||
| 2022-09-30 | $205.37M 10-Q · filed 2023-11-08 | $400.38M derived: sum of 2 quarters · filed 2023-11-08 | $572.59M 10-Q · filed 2023-11-08 | $700.14M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | $195.00M 10-Q · filed 2023-08-04 | $367.22M 10-Q · filed 2023-08-04 | $494.77M derived: sum of 3 quarters · filed 2023-08-04 | $617.06M derived: sum of 4 quarters · filed 2023-08-04 |
| 2022-03-31 | $172.22M 10-Q · filed 2023-05-09 | $299.77M derived: sum of 2 quarters · filed 2023-05-09 | $422.05M derived: sum of 3 quarters · filed 2023-05-09 | $550.71M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $127.55M 10-K · filed 2022-03-01 | $249.84M derived: sum of 2 quarters · filed 2022-11-04 | $378.49M derived: sum of 3 quarters · filed 2022-11-04 | $500.62M 10-K · filed 2022-03-01 |
| 2021-09-30 | $122.28M 10-Q · filed 2022-11-04 | $250.94M derived: sum of 2 quarters · filed 2022-11-04 | $373.07M 10-Q · filed 2022-11-04 | $473.37M derived: sum of 4 quarters · filed 2022-11-04 |
| 2021-06-30 | $128.65M 10-Q · filed 2022-08-05 | $250.78M 10-Q · filed 2022-08-05 | $351.08M derived: sum of 3 quarters · filed 2022-08-05 | $450.01M derived: sum of 4 quarters · filed 2022-08-05 |
| 2021-03-31 | $122.13M 10-Q · filed 2022-05-06 | $222.43M derived: sum of 2 quarters · filed 2022-05-06 | $321.36M derived: sum of 3 quarters · filed 2022-05-06 | $385.97M derived: sum of 4 quarters · filed 2022-05-06 |
| 2020-12-31 | $100.30M 10-K · filed 2022-03-01 | $199.23M derived: sum of 2 quarters · filed 2022-03-01 | $263.83M derived: sum of 3 quarters · filed 2022-03-01 | $344.86M 10-K · filed 2022-03-01 |
| 2020-09-30 | $98.93M 10-K · filed 2022-03-01 | $163.53M derived: sum of 2 quarters · filed 2022-03-01 | $244.56M 10-Q · filed 2021-11-08 | $309.68M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $64.61M 10-K · filed 2022-03-01 | $145.63M 10-Q · filed 2021-08-06 | $210.75M derived: sum of 3 quarters · filed 2022-03-01 | $271.95M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $81.02M 10-K · filed 2022-03-01 | $146.15M derived: sum of 2 quarters · filed 2022-03-01 | $207.34M derived: sum of 3 quarters · filed 2022-03-01 | $263.51M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $65.12M 10-K · filed 2021-03-01 | $126.32M derived: sum of 2 quarters · filed 2021-03-01 | $182.49M derived: sum of 3 quarters · filed 2021-03-01 | $229.68M 10-K · filed 2022-03-01 |
| 2019-09-30 | $61.20M 10-K · filed 2021-03-01 | $117.36M derived: sum of 2 quarters · filed 2021-03-01 | $164.56M 10-Q · filed 2020-11-06 | $193.75M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | $56.17M 10-K · filed 2021-03-01 | $103.36M 10-Q · filed 2020-08-07 | $132.55M derived: sum of 3 quarters · filed 2021-03-01 | $160.35M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | $47.20M 10-K · filed 2021-03-01 | $76.38M derived: sum of 2 quarters · filed 2021-03-01 | $104.18M derived: sum of 3 quarters · filed 2021-03-01 | $130.34M derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | $29.19M 10-K · filed 2020-03-10 | $56.98M derived: sum of 2 quarters · filed 2020-03-10 | $83.14M derived: sum of 3 quarters · filed 2020-03-10 | $105.40M 10-K · filed 2021-03-01 |
| 2018-09-30 | $27.80M 10-K · filed 2020-03-10 | $53.95M derived: sum of 2 quarters · filed 2020-03-10 | $76.21M 10-Q · filed 2019-12-06 | |
| 2018-06-30 | $26.16M 10-K · filed 2020-03-10 | $48.41M derived: sum of 2 quarters · filed 2020-03-10 | ||
| 2018-03-31 | $22.26M 10-K · filed 2020-03-10 | |||
| 2017-12-31 | $48.58M 10-K · filed 2020-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| agilon health, inc. (AGL) | United States | $1.272B | -7.76 |
| VIEMED HEALTHCARE, INC. (VMD) | United States | $0.336B | 29.92 |
| Park Dental Partners, Inc. (PARK) | United States | $0.094B | |
| BioRestorative Therapies, Inc. (BRTX) | United States | $0.064B | |
| CRYO CELL INTERNATIONAL INC (CCEL) | United States | $0.033B | -11.02 |
| MANGOCEUTICALS, INC. (MGRX) | United States | $0.010B | -0.43 |
| Sotera Health Co (SHC) | United States | $5.271B | 30.96 |
| DAVITA INC. (DVA) | United States | $11.147B | 16.80 |